吲哚布芬联合替格瑞洛治疗急性冠脉综合征介入术后患者的疗效及成本-效果分析  

Efficacy and cost-effectiveness analysis of indobufen combined with ticagrelor in treating patients with acute coronary syndrome after intervention operation

作　　者：胡顺 HU Shun(Department of the Pharmacy,Lianshui County People's Hospital,Huai'an 215000,China)

机构地区：[1]涟水县人民医院药剂科,江苏淮安215000

出　　处：《中国处方药》2025年第5期70-73,共4页Journal of China Prescription Drug

摘　　要：目的探讨吲哚布芬联合替格瑞洛治疗急性冠脉综合征(ACS)介入术后患者的疗效及成本-效果分析。方法选取2022年3月~2024年6月涟水县人民医院接受经皮冠状动脉介入治疗(PCI)术后的62例ACS患者,采用随机信封法分为参照组(予以阿司匹林联合替格瑞洛治疗,n=31)和研究组(予以吲哚布芬联合替格瑞洛治疗,n=31)。治疗2个月后,比较两组疗效、血小板聚集指标[血小板聚集率(MPAR)和P2Y12反应单位(PRU)]、冠脉血流参数[收缩期峰流速(SPV)、舒张期峰流速(DPV)和冠脉血流储备(CFVR)]、不良事件发生情况、成本-效果分析结果。结果研究组治疗总有效率为93.55%,高于参照组的74.19%(P<0.05);治疗后,两组的MPAR、PRU均降低,且研究组均低于参照组(P<0.05),两组的SPV、DPV和CFVR均升高,且研究组高于参照组(P<0.05);研究组不良事件发生率为3.23%,低于参照组的19.35%(P<0.05);根据患者的用药费用以及发生不良事件后的治疗情况,参照组总费用为8772.56元,成本效果之比(CER)为108.77元,研究组总费用为43307.00元,CER为447.52元,不良事件发生率每降低1%,研究组比参照组多支付338.76元。结论吲哚布芬联合替格瑞洛治疗行PCI术后ACS患者疗效显著,可以显著抑制患者的血小板聚集情况,改善冠脉血流情况,同时还能降低不良事件发生情况,且成本-效用优于阿司匹林联合替格瑞洛。Objective To investigate the efficacy and cost-effectiveness of indobufen combined with ticagrelor in patients with acute coronary syndrome(ACS)after percutaneous coronary intervention(PCI).Methods A total of 62 ACS patients who underwent PCI at Lianshui County People’s Hospital from March 2022 to June 2024 were selected and randomly divided into the control group(treated with aspirin combined with ticagrelor,n=31)and the study group(treated with indobufen combined with ticagrelor,n=31)using the random envelope method.After 2 months of treatment,the efficacy,platelet aggregation indices[maximum platelet aggregation rate(MPAR)and P2Y12 reaction units(PRU)],coronary flow parameters[systolic peak velocity(SPV),diastolic peak velocity(DPV),and coronary flow velocity reserve(CFVR)],incidence of adverse events,and cost-effectiveness analysis results were compared between the two groups.Results The total effective rate in the study group was 93.55%,significantly higher than 74.19%in the control group(P<0.05).After treatment,MPAR and PRU decreased in both groups,with lower values observed in the study group(P<0.05).SPV,DPV,and CFVR increased in both groups,with higher values in the study group(P<0.05).The incidence of adverse events in the study group was 3.23%,lower than 19.35%in the control group(P<0.05).Based on medication costs and post-adverse event treatment expenses,the total cost for the control group was 8772.56 yuan(cost-effectiveness ratio,CER=108.77 yuan),while for the study group,it was 43307.00 yuan(CER=447.52 yuan).For every 1%reduction in adverse events,the study group incurred an additional cost of 338.76 yuan compared to the control group.Conclusion Indobufen combined with ticagrelor demonstrates significant efficacy in ACS patients post-PCI,effectively inhibiting platelet aggregation,improving coronary blood flow,reducing adverse events,and offering superior cost-effectiveness compared to aspirin combined with ticagrelor.

关 键 词：吲哚布芬 替格瑞洛 急性冠脉综合征介入术 疗效 成本-效果分析 

分 类 号：R54[医药卫生—心血管疾病]